Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease
, 1, 1, 1, 2, 2, 34, 34, 5, 5, 5, 6, 6, 7, 7, 89, 1
Abstract
Aim of study. To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG.
Clinical rationale for study. Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson’s Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG.
Material and methods. A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing.
Results. Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695–3,184) and 1,898 (1,484–2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy.
Conclusions and clinical implications. The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.
Keywords: acute polyneuropathyParkinson’s Diseaselevodopa/carbidopa intestinal gellevodopa equivalent daily dose
References
- Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Annals of Neurology. 2010; 68(1): 28–36.
- Artusi CA, Balestrino R, Imbalzano G, et al. Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors, Parkinsonism Relat Disord. Parkinsonism Relat Disord . 2020(76): 98–103.
- Loens S, Chorbadzhieva E, Kleimann A, et al. Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain Behav . 2017; 7(5): e00698.
- Galazky I, Schoof J, Stallforth S. Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism Relat Disord. 2014; 20(1): 125–7.
- Merola A, Zibetti, M, Romagnolo MA, et al. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016; 23(3): 501–9.
- Klostermann F, Jugel C, Muller T. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012; 119(3): 369–72.
- Tomlinson C, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders. 2010; 25(15): 2649–2653.
- Stoker TB, Greenland JC. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane. 1018(AU): 2018.
- Mirian A, Aljohani Z, Grushka D, et al. Diagnosis and management of patients with polyneuropathy. Canadian Medical Association Journal. 2023; 195(6): E227–E233.
- Zadikoff C, Poewe W, Boyd JT, et al. Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa. Parkinsons Dis. 2020: 9716317.
- Piekarski R, Roszmann A, Dulski J, et al. Acute/subacutae demyelinating polyneuropathy in Parkinson’s Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report. Neurologia i Neurochirurgia Polska. 2023; 57(2): 169–176.
- A. Uncini, R. Eleopra, M. Onofrj, Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management, J Neurol Neurosurg Psychiatry. 2015; 86(5): 490–5.
- Piekarski R, Roszmann A, Dulski J, et al. Response to ‘Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out’. Neurologia i Neurochirurgia Polska. 2023; 57(4): 403–404.
- Finsterer J. Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out. Neurologia i Neurochirurgia Polska. 2023; 57(4): 401–402.
- Lehnerer SM, Fietzek UM, Messner M, et al. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm (Vienna). 2014; 121(10): 1269–72.
- Andréasson M, Brodin L, Laffita-Mesa J, et al. Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson’s Disease: A Preliminary Cross-Sectional Study. Journal of Parkinson's Disease. 2017; 7(4): 619–628.
- Martino JV, Van Limbergen J, Cahill LE. The Role of Carrageenan and Carboxymethylcellulose in the Development of Intestinal Inflammation. Front Pediatr . 2017; 5: 96.
